Evidence map›Paper›PMID 42512568›Full record

ReviewHealthcare (Basel, Switzerland)2026

Clinical AI Beyond Development: A Scoping Review of Deployment-Related Robustness, Algorithmovigilance, and Lifecycle Oversight.

Rabie Adel El Arab, Mohammad Hussein Mustafa, Wesam Taher Almagharbeh, Mohammad Yahya Ayoub, Fatimah Alsanawi, Fulwa Almathen, Rawan Almosabeh, Magfrah Al Talaq

Abstract readReview
In one paragraph

Review in Healthcare (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rabie Adel El ArabAlmoosa College of Health Sciences, Al Ahsa 36422, Saudi Arabia.ORCID 0000-0002-3822-9236
Mohammad Hussein MustafaDr. Sulaiman Alhabib Medical Group, Riyadh 71491, Saudi Arabia.ORCID 0009-0007-2937-4347
Wesam Taher AlmagharbehMedical and Surgical Nursing Department, Faculty of Nursing, University of Tabuk, Tabuk 71491, Saudi Arabia.ORCID 0000-0002-8435-1208
Mohammad Yahya AyoubDr. Sulaiman Alhabib Medical Group, Riyadh 71491, Saudi Arabia.ORCID 0009-0007-2323-0369
Fatimah AlsanawiAlmoosa College of Health Sciences, Al Ahsa 36422, Saudi Arabia.
Fulwa AlmathenAlmoosa College of Health Sciences, Al Ahsa 36422, Saudi Arabia.
Rawan AlmosabehAlmoosa College of Health Sciences, Al Ahsa 36422, Saudi Arabia.
Magfrah Al TalaqAlmoosa College of Health Sciences, Al Ahsa 36422, Saudi Arabia.

Funding

Almoosa College of Health Sciences will cover APC 1232
6 · The paper itself

Abstract

BACKGROUND/

objectivesClinical artificial intelligence (AI) is increasingly moving from proof-of-concept development into clinical evaluation, regulatory review, and routine care. This scoping review aimed to map and synthesise empirical evidence on clinical AI evaluation after model development, focusing on deployment-related robustness, post-development monitoring, and lifecycle oversight in practice.

methodsWe conducted a scoping review in accordance with Joanna Briggs Institute guidance and reported findings using PRISMA-ScR. MEDLINE, Embase, Scopus, and Web of Science Core Collection were searched with no lower date restriction within each database's available indexed coverage and with a common upper search date of 28 February 2026. Searches were supplemented by backward and forward citation tracking. Grey literature, preprint servers, and regulatory databases were not systematically searched because eligibility was restricted to full-text, peer-reviewed empirical studies and empirically grounded implementation or monitoring reports. Findings were synthesised using descriptive evidence mapping and inductive thematic synthesis.

resultsEighteen studies or empirically grounded reports were included. Evidence was organised into five strata: direct live or post-deployment monitoring studies; near-live bridge studies generating prospective outputs without guiding care; methodological monitoring and maintenance studies; deployment-relevant robustness and predeployment safety studies; and governance, implementation, readiness, and human-factors studies. Three themes emerged: trustworthiness after development was conditional and context-dependent; algorithmovigilance extended beyond aggregate performance tracking to include operational, workflow, fairness, contextual, and user-feedback signals; monitoring was more actionable when linked to corrective pathways, governance structures, and institutional readiness. Sociotechnical failures included automation-bias signals, workflow burden, reasoning-conclusion misalignment, and workflow-fit problems.

conclusionsPost-development clinical AI evaluation remains a layered and emerging field rather than a mature monitoring literature. Direct live evidence is limited, concentrated in high-income settings, and weighted towards radiology. The findings should be interpreted as synthesis-informed rather than as empirically validated standards for lifecycle oversight.

Indexed as

algorithmovigilanceclinical artificial intelligencedeployment-related robustnesslifecycle oversightpost-deployment monitoringpost-development evaluationreal-world evaluation

Identifiers

PMID42512568
PMCPMC13409740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.